Patient self-report tool on side effects in cancer clinical trials validated by landmark study
the ONA take:
A landmark study has validated the National Cancer Institute’s Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) as an accurate, reliable, and responsive measure of side effects experienced by patients participating in clinical trials. This study compared the PRO-CTCAE with other patient-reported and clinical measures.
More than 1,000 patients from clinical practices across the United States, including seven cancer centers, were recruited to participate in the study.
They were asked to complete the PRO-CTCAE before appointments. Their reports were compared against other established measures of symptoms such as case and quality of life reports and prescription information.
The researchers validated 119 of 125 PRO-CTCAE questions against the established measurement tools usually based on information from providers. Underrepresentation in the study population prohibited evaluation of the five questions that could not be validated.
This study was unique in that more than 100 distinct questions about symptomatic adverse events were validated simultaneously.
The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is accurate, reliable.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|